Literature DB >> 2972251

Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.

R Kurlan1, D Goldblatt, R Zaczek, K Jeffries, C Irvine, J Coyle, I Shoulson.   

Abstract

In Huntington's disease (HD), normal or decreased levels of homovanillic acid (HVA) in cerebrospinal fluid (CSF) have been reported but have not been analyzed with respect to severity of parkinsonism, which in certain cases may be a predominant feature of the illness. We obtained CSF by lumbar puncture from four groups of nonmedicated subjects: (1) those with HD in the earliest stages of illness (n = 51), (2) those with parkinsonism, including idiopathic (n = 10) and atypical forms (n = 4), (3) those with nonparkinsonian movement disorders (n = 19), and (4) normal volunteers (n = 4). HVA was determined by high-pressure liquid chromatography with electrochemical detection, and motor signs were assessed in standardized fashion. The parkinsonian group had reduced levels of CSF HVA, but the other groups showed no significant differences. For those with HD, no correlation was found between HVA level and severity of parkinsonism, and there were no differences in HVA level between those subjects with (n = 14) or without (n = 37) prominent parkinsonism or between subjects whose age at illness onset was 30 years or less (n = 16) and those whose age at onset was over 30 (n = 35). Our findings indicate that in early, untreated HD, CSF HVA is in the normal range and does not correlate with the severity of parkinsonism. This observation supports neuropathological findings suggesting that parkinsonian features in HD are largely related to the loss of postsynaptic striatal dopamine receptors rather than to presynaptic nigral degeneration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972251     DOI: 10.1002/ana.410240221

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  4 in total

1.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

2.  Plasma homovanillic acid and prolactin in Huntington's disease.

Authors:  Manolis Markianos; Marios Panas; Nikos Kalfakis; Dimitrios Vassilopoulos
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

3.  A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Authors:  Herminia D Rosas; Gheorghe Doros; Swati Bhasin; Beena Thomas; Sona Gevorkian; Keith Malarick; Wayne Matson; Steven M Hersch
Journal:  Ann Clin Transl Neurol       Date:  2015-05-28       Impact factor: 4.511

4.  Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.

Authors:  Christiana C Christodoulou; Margarita Zachariou; Marios Tomazou; Evangelos Karatzas; Christiana A Demetriou; Eleni Zamba-Papanicolaou; George M Spyrou
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.